^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    megestrol

    i
    Other names: BDH 1298
    Company:
    Generic mfg.
    Drug class:
    Progesterone receptor agonist
    7d
    Treatment of HRD-positive elderly ovarian cancer patient: a case report. (PubMed, Anticancer Drugs)
    Fluzoparib, the domestically developed PARPi in China, has demonstrated significant efficacy in BRCA-mutated ovarian cancer. In the field of supportive care, megestrol acetate (MA) is recommended as the first-line preferred therapeutic agent for cancer-related anorexia by major guidelines, though its role in first-line ovarian cancer therapy remains unexplored, and evidence for its combination with PARPi is lacking...Imaging assessments revealed significant tumor reduction without disease progression or grade ≥3 adverse events observed throughout follow-up. This case highlights the potential of combining PARPi and hormone therapy as a 'chemotherapy-free' precision treatment model for elderly and HRD-positive ovarian cancer patients, offering a promising strategy to balance efficacy and tolerability in a population traditionally underserved by conventional regimens.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    AiRuiYi (fluzoparib) • megestrol
    7d
    A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients (clinicaltrials.gov)
    P4, N=120, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P4 trial
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • megestrol
    14d
    A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia (clinicaltrials.gov)
    P4, N=495, Recruiting, Changchun GeneScience Pharmaceutical Co., Ltd.
    New P4 trial • Real-world evidence
    |
    megestrol
    2ms
    Enhanced efficacy and safety of combining Aidi injection with megestrol acetate for endometrial cancer treatment. (PubMed, Am J Transl Res)
    Aidi injection combined with MA provided a promising therapeutic strategy for EC. This regimen effectively inhibited tumor progression, improveed quality of life, and decreased serum tumor marker levels (HE4, CEA, and CA125), supporting its potential for broader clinical application.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CTGF (Connective tissue growth factor)
    |
    megestrol
    2ms
    Challenges in Fertility Preservation for p53abn Grade 2 Endometrioid Endometrial Cancer: A Case Report and Literature Review. (PubMed, Reprod Sci)
    Her initial treatment involved hysteroscopy-guided resection, hormonal therapy with megestrol acetate (MA), and close monitoring, but the disease recurred within six months...This case underscores the essential role of molecular profiling in clinical decision-making and the need for ongoing research into molecular pathways. Integrating molecular classifiers into routine practice is crucial for improving risk stratification and treatment outcomes, especially in young women pursuing fertility preservation.
    Journal
    |
    PTEN (Phosphatase and tensin homolog)
    |
    PTEN mutation
    |
    megestrol
    3ms
    Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101 (clinicaltrials.gov)
    P2, N=135, Not yet recruiting, MetaFines
    New P2 trial
    |
    megestrol
    3ms
    Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer (clinicaltrials.gov)
    P2, N=51, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    megestrol
    3ms
    Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=134, Recruiting, Changchun GeneScience Pharmaceutical Co., Ltd.
    New P3 trial
    |
    megestrol
    4ms
    Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy (clinicaltrials.gov)
    P1, N=132, Not yet recruiting, Changchun GeneScience Pharmaceutical Co., Ltd.
    New P1 trial
    |
    megestrol
    4ms
    Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting (clinicaltrials.gov)
    P3, N=126, Not yet recruiting, The First Affiliated Hospital of Xinxiang Medical College
    New P3 trial
    |
    megestrol • fosaprepitant • ondansetron
    4ms
    A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) (clinicaltrials.gov)
    P2, N=250, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting | Trial completion date: Jul 2030 --> Nov 2027 | Trial primary completion date: Jul 2030 --> Nov 2027
    Enrollment open • Trial completion date • Trial primary completion date • Pan tumor
    |
    tamoxifen • fulvestrant • letrozole • exemestane • megestrol • opevesostat (MK-5684)
    4ms
    Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma (clinicaltrials.gov)
    P2, N=48, Completed, Fudan University | Active, not recruiting --> Completed
    Trial completion
    |
    megestrol